Local Delivery of Vaccinia Virus Expressing Multiple Costimulatory Molecules for the Treatment of Established Tumors
- 1 February 2006
- journal article
- research article
- Published by SAGE Publications in Human Gene Therapy
- Vol. 17 (2) , 239-244
Abstract
Successful immunotherapy of established tumors depends on overcoming the suppressive influence of the local tumor microenvironment. The direct injection of vaccinia virus expressing the B7.1 (CD80) costimulatory molecule into melanoma lesions resulted in local and systemic immunity with associated clinical responses. Therefore, we sought to evaluate the effects of a vaccinia virus expressing three costimulatory molecules, B7.1, ICAM-1, and LFA-3 (rV-TRICOM), in patients with metastatic melanoma. A standard dose escalation phase I clinical trial was performed. Thirteen patients were enrolled and 12 were available for follow-up. Local vaccination was feasible, with only low-grade injection site reactions associated with mild fatigue and myalgia reported. There was one occurrence of grade 1 vitiligo. Overall there was a 30.7% objective clinical response, with one patient achieving a complete response for more than 22 months. An inverse association was detected between anti-vaccinia antibody and anti-vaccinia T cell responses. Patients who failed to respond to vaccination but received high-dose interleukin-2 had a trend toward improved survival. Collectively, these results confirm the safety profile and feasibility of direct injection of vaccinia virus expressing multiple costimulatory molecules in patients with established tumors. Further clinical investigation is needed to better define the role of antigen, adjuvant cytokines, costimulation, and cross-presentation in the host immune response to local vaccination with vaccinia viruses expressing immunomodulatory molecules.Keywords
This publication has 18 references indexed in Scilit:
- Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanomaJournal of Clinical Investigation, 2005
- Multiple Costimulatory Modalities Enhance CTL AvidityThe Journal of Immunology, 2005
- Induction of an Antigen Cascade by Diversified Subcutaneous/Intratumoral Vaccination Is Associated with Antitumor ResponsesClinical Cancer Research, 2005
- Amplification of the lytic potential of effector/memory CD8+ cells by vector-based enhancement of ICAM-1 (CD54) in target cells: implications for intratumoral vaccine therapyCancer Gene Therapy, 2004
- Expression of the B7.1 Costimulatory Molecule on Pancreatic β Cells Abrogates the Requirement for CD4 T Cells in the Development of Type 1 DiabetesThe Journal of Immunology, 2004
- Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunityNature Reviews Immunology, 2004
- Relevance of tumor microenvironment for progression, therapy and drug developmentAnti-Cancer Drugs, 2004
- The tumor microenvironment: a critical determinant of neoplastic evolutionEuropean Journal of Cell Biology, 2003
- A Phase I Trial of Intralesional rV-Tricom Vaccine in the Treatment of Malignant MelanomaHuman Gene Therapy, 2001
- Irradiated NC Adenocarcinoma Cells Transduced with Both B7.1 and Interleukin-2 Induce CD4 + -Mediated Rejection of Established TumorsHuman Gene Therapy, 1997